The historical rank and industry rank for PT Pyridam Farma Tbk's Net Margin % or its related term are showing as below:
ISX:PYFA'
s Net Margin % Range Over the Past 10 Years
Min: -17.19 Med: 2.79 Max: 38.47
Current: -13.02
ISX:PYFA's Net Margin % is ranked worse than 77.75% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs ISX:PYFA: -13.02
PT Pyridam Farma Tbk (ISX:PYFA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PT Pyridam Farma Tbk Net Margin % Related Terms
PT Pyridam Farma Tbk Net Margin % Historical Data
* Premium members only.
The historical data trend for PT Pyridam Farma Tbk's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PYFA vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Pyridam Farma Tbk Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's Net Margin % distribution charts can be found below:
* The bar in red indicates where PT Pyridam Farma Tbk's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Pyridam Farma Tbk (ISX:PYFA) has a Net Margin % of -10.55% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on PT Pyridam Farma Tbk and its competitors. According to the industry distribution chart, PT Pyridam Farma Tbk ranks #741 out of 953 companies in the Drug Manufacturers industry, placing it in the top 77.8%.
Is PT Pyridam Farma Tbk's Net Margin % too high?
PT Pyridam Farma Tbk's current Net Margin % is -10.55%. Based on the distribution chart, PT Pyridam Farma Tbk ranks #741 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Pyridam Farma Tbk has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Pyridam Farma Tbk ranks #741 out of 953 companies for Net Margin %. This places PT Pyridam Farma Tbk in the lower half of its industry. The industry median Net Margin % is 5.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PT Pyridam Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Pyridam Farma Tbk's current Net Margin % is -10.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp212.90, compared to a current price of Rp182.00 — trading 14.5% below its estimated fair value. The current Net Margin % is -10.55%. PT Pyridam Farma Tbk's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Net Margin % is -10.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued.
The current stock price of Rp182.00 is trading 14.5% below its estimated GF Value™ of Rp212.90.
GuruFocus considers PT Pyridam Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PYFA:
Net Margin %: -10.55%
GF Value™: Rp212.90 vs. price of Rp182.00 (14.5% below fair value)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
68GF Score
Get the complete analysis for ISX:PYFA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
